Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
I

Inuvo Inc
F:CD5N

Watchlist Manager
Inuvo Inc
F:CD5N
Watchlist
Price: 4 EUR -9.5% Market Closed
Market Cap: €560.6m
Write Note Create Alert Ask AI

Wall St Price Targets

CD5N Price Targets Summary
Inuvo Inc

Wall Street analysts forecast CD5N stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CD5N is 25.89 EUR with a low forecast of 15.54 EUR and a high forecast of 38.77 EUR.

CD5N Lowest Forecast
Wall Street Target
€15.54
288% Upside
CD5N Average Forecast
Wall Street Target
€25.89
547% Upside
CD5N Highest Forecast
Wall Street Target
€38.77
869% Upside
Lowest Forecast
Price Target
15.54 EUR
288% Upside
Average Forecast
Price Target
25.89 EUR
547% Upside
Highest Forecast
Price Target
38.77 EUR
869% Upside
Inuvo Inc Competitors:
Price Targets
IMNM
Immunome Inc
39% Upside
O
SBT
Oeneo SA
13% Upside
NOA
North American Construction Group Ltd
38% Upside
ZM
Zoom Video Communications Inc
24% Upside
IMNM
Immunome Inc
39% Upside
O
SBT
Oeneo SA
13% Upside
NOA
North American Construction Group Ltd
38% Upside
ZM
Zoom Video Communications Inc
24% Upside

Revenue
Forecast

4% / Year
Past Growth
-22% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
4% / Year
Past Growth
-22% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 3 years is -22%.

What are analyst estimates?

Gross Profit
Forecast

7% / Year
Past Growth
-7% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
7% / Year
Past Growth
-7% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 7%. The projected CAGR for the next 3 years is -7%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
6%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
6%
Average Beat

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
6%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
6%
Average Beat

What are analyst estimates?

Continue CD5N Research

Summary
CD5N intrinsic value, competitors valuation, and company profile.
DCF Valuation
CD5N stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CD5N stock valuation using valuation multiples.
Wall St Estimates
CD5N price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CD5N stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Inuvo Inc listings:
AMEX • USD
INUV
 F • EUR
CD5
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is CD5N's stock price target?
Price Target
25.89 EUR

According to Wall Street analysts, the average 1-year price target for CD5N is 25.89 EUR with a low forecast of 15.54 EUR and a high forecast of 38.77 EUR.

What is the Revenue forecast for Inuvo Inc?
Projected CAGR
-22%

Over the last 13 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 3 years is -22%.

What is the Gross Profit forecast for Inuvo Inc?
Projected CAGR
-7%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 7%. The projected CAGR for the next 3 years is -7%.

Back to Top
ALPHA SPREAD
Follow us
Join 356,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett